PPD takes Pharmacovigilance to Bulgaria
Many companies that specialise in pharmacovigilance have sprung up in recent years. In addition, a number of others have enjoyed major growth.
One firm that falls into the latter category is PPD, a leading global contract research organisation with around 25 years of experience in drug discovery, development and lifecycle management services. Notably, the organisation has much experience in the world of pharmacovigilance and is looking to take the concept into new territories across the globe.
The company recently opened a new centre in Sofia, Bulgaria, where its staff will provide medical information call centre support and scientists will also be on hand to work on pharmacovigilance projects.
More specifically, the experts will consider a number of issues including adverse event capture, safety case processing and reporting, and periodic writing services. As the area is home to several medical and pharmacy schools, the centre is likely to be able to recruit highly-trained healthcare professionals with extensive language capabilities locally. Nurses, physicians and pharmacists will be employed on-site, as PPD aims to have more than 200 professionals working there within the next 12 months.
Dr. Christine Dingivan, chief medical officer at PPD, suggested the decision to establish the base in Bulgaria was driven by rising demand for pharmacovigilance across the globe.
"Expanding our safety and medical communications operations in Europe strengthens our ability to bring high-quality global healthcare expertise to provide these services in an efficient, cost-effective and regulatory compliant manner," she explained.
"There is strong demand for both pre and post-approval safety services, and we have an experienced management team on the ground in Bulgaria to oversee our operations and to create customised programs that meet client needs."
The new site in Sofia will be PPD's third European hub, as it already runs operations from a facility in Athlone, Ireland, as well as contact centre services in the Swedish capital Stockholm.
While the move is set to bring major benefits to the company, particularly through expanding the range of the company's pharmacovigilance services, the country of Bulgaria is also likely to prosper.
James Warlick, the US ambassador to Bulgaria, said PPD was making "a significant investment" in an "important technical field" which could play a major part in the country's future.
"Bulgaria has a noteworthy and rich history of innovation and technology, and both PPD and the people of Bulgaria can benefit from this venture," he explained.
"The US Embassy looks forward to further strengthening our relationship with PPD as it expands in this region."
The growth that PPD is enjoying is not only evidence of the firm's own good fortunes, but also the increasing demand that is emerging for pharmacovigilance services across the globe. In a way its importance should not be surprising, particularly as drug developers could put their reputations – and potentially the lives of patients – in jeopardy by failing to take the concept into account.
As drug safety remains such a fundamental aspect of the pharmaceutical industry, it is likely that more firms will experience similar growth to PPD – which in turn will make pharmacoviligance a truly global concern.
Found this interesting?
You may like to also have a look at Adverse Event Reporting - Online Training Course (link to https://www.adverseeventreportingtraining.com/)